#Plexium is looking to expand our team of drug hunters, with openings for positions such as Principal Scientist and Process Engineer! Check out our careers page for more details! #proteindegradation

Our approach to TPD is highlighted in poster #1283 at this year's AACR meeting. We describe the discovery & unique profile of a non-PROTAC selective degrader of BRD4 for the treatment of myc-driven tumors. "Discovery of potent & selective degraders of BRD4 using DELPhe platform"

Big news today – we closed a $35M financing w/ @Lux_Capital, Pivotal Bioventures, The Column Group, @DCVC and other outstanding investors to help us advance our pipeline of novel protein degraders. We’re also thrilled to welcome Mike Grey as Chairman! prn.to/39QkchL

Don’t miss Plexium CEO Kandaswamy Vijayan’s presentation on “Degrading ‘Undruggable’ Proteins with Molecular-Glues” today at the 2nd Targeted Protein Degradation Summit: bit.ly/2VW40Ej #biotech #drugdiscovery #drugdevelopment #cancer #oncology #neurodegeneration #Boston

Plexium CEO Kandaswamy Vijayan to present on “Degrading ‘Undruggable’ Proteins with Molecular-Glues” at the 2nd Targeted Protein Degradation Summit on Oct. 23 at 12:30 pm: bit.ly/2VW40Ej #biotech #drugdiscovery #cancer #oncology #neurodegeneration #Boston

Plexium launches with $28M Series A financing to advance DELPhe platform, cell-based screening of DNA-encoded libraries in nanoliter volumes, to discover novel E3 ligase-modulating drugs bit.ly/2OP8Guh #biotech #drugdiscovery #cancer #oncology #neurodegeneration